

# **CURRICULUM VITAE**

**ZENAS Z. N. YIU**

**BSc**

**MBChB**

**MRCP (Dermatology)**

**MSc**

**PhD**

## Personal details

**Name:** Zenas Zee Ngai Yiu  
**Address:** The Centre for Dermatology Research  
1<sup>st</sup> Floor Barnes Building, Salford Royal Hospital  
Northern Care Alliance NHS Foundation Trust  
Salford, UK, M6 8HD  
**Email address:** zenas.yiu@manchester.ac.uk  
zenas.yiu@nca.nhs.uk  
**Academic personal website:** <http://personalpages.manchester.ac.uk/staff/zenas.yiu>  
**ORCID:** [orcid.org/0000-0002-1831-074X](http://orcid.org/0000-0002-1831-074X)

## Career biography

Dr Zenas Yiu is a Clinical Senior Lecturer in Dermatology and Pharmacoepidemiology at the University of Manchester, and an Honorary Consultant Dermatologist at the Northern Care Alliance NHS Foundation Trust. He studied medicine and trained in Dermatology in Manchester, and was awarded a NIHR Doctoral Research Fellowship in 2015 to pursue his doctorate degree investigating the risk of serious infection in patients with psoriasis on biologic therapies. He also holds a Master's degree in Epidemiology from the London School of Hygiene and Tropical Medicine. He was awarded the Royal Society of Medicine Dermatology Trainee Research Prize in 2018, and the Royal College of Physicians Turner-Warwick Lectureship for the North West region in 2019 for his doctorate research. He works in regional tertiary clinics for psoriasis and hidradenitis suppurativa, and has research interests in Pharmacoepidemiology, Clinical Practice Guidelines, and Evidence-Based Dermatology. He sits on the steering committee for three British Association of Dermatologists (BAD) research projects on psoriasis (BADBIR), alopecia areata (GRASS-UK), and keratinocyte cancer (UKKCC); and on the BAD research subcommittee. He sits on the Technology Appraisal Committee for the National Institute for Health and Care Excellence to evaluate health technologies. He works as an editor for Cochrane Skin and an associate editor for the BJD for guidelines. He takes a particular interest in the evaluation of the safety and effectiveness of therapeutics for chronic inflammatory skin conditions.

## Qualifications

### *Degrees*

- Bachelor of Medicine, Bachelor of Surgery (MBChB), The University of Manchester, UK (2009)
- Bachelor of Anatomical Sciences (Intercalated BSc), The University of Manchester, UK (2006)
- Master of Science (MSc) in Epidemiology, London School of Hygiene and Tropical Medicine, UK (2019)
- Doctor of Philosophy in Medicine (PhD), The University of Manchester, UK (2018)

### Postgraduate certificates

- Specialty Certificate in Dermatology, Royal Colleges of Physicians (UK), November 2015
- Membership of the Royal Colleges of Physicians (UK), March 2012
- International Guideline Development Credentialing & Certification Program (INGUIDE) Level 1: Guideline Panel Member Certificate, Guidelines International Network, June 2022

## Present positions

**Role:** Clinical Senior Lecturer in Dermatology. The University of Manchester  
**Duration of employment:** 4<sup>th</sup> July 2022 - Present

**Role:** Honorary Consultant Dermatologist, Northern Care Alliance NHS Foundation Trust  
**Duration of employment:** 5<sup>th</sup> July 2021 - Present

**Role:** Associate Editor for the Guidelines subsection, Evidence-based Dermatology, British Journal of Dermatology  
**Duration of employment:** 1<sup>st</sup> August 2017 – Present

**Role:** Editor for Cochrane Skin  
**Duration of employment:** April 2023 – Present

**Role:** National Institute for Health and Care Excellence Technology Appraisal Committee  
**Duration of employment:** July 2023 – Present

### **Previous research positions**

- NIHR Academic Foundation Doctor in Dermatology, 2009-2011
- NIHR Academic Clinical Fellow in Dermatology, 2012-2015
- NIHR Doctoral Research Fellow in Dermatology and Pharmacoepidemiology, 2015-2018
- NIHR Academic Clinical Lecturer in Dermatology, 2019-2022

### **Fellowship and grants**

- NIHR Doctoral Research Fellowship, entitled: "Risk and predictors of infections in psoriasis patients exposed to biologic therapy: a prospective observational cohort study in the British Association of Dermatologists' Biologic Interventions Register (BADBIR)", reference DRF-2015-08-089, £260,814
- PhD studentship 2021, Psoriasis Association, entitled: "Evaluation of Tumour Necrosis Factor Inhibitor Biosimilar Use in the UK: a study from the British Association of Dermatologists Biologics and Immunomodulator Register", Principal Investigator and Supervisor, £85,500
- PhD studentship 2022, Psoriasis Association, entitled: "Risk of Serious Infection associated with Interleukin 17 and 23 Inhibitors Compared with Other Biologics in People with Psoriasis", Principal Investigator and Supervisor, £85,500
- Turing-Manchester Feasibility Project Sandpit grant 2022, entitled: "Journey of patients with suspected cancer in Greater Manchester – skin cancer as an exemplar", Co-lead Principal Investigator, £10,000
- Turing-Manchester Feasibility Project Sandpit grant 2022, entitled: "Exploring the feasibility and clinical risks of integrating free-text electronic healthcare records (EHR) data into an existing Knowledge Support System (KSS) to support clinical decision-making during primary care consultations with mental health patients", Co-investigator, £10,000
- NIHR School for Primary Care Research grant 2023, entitled: "The association between the COVID-19 vaccine and skin conditions", Co-investigator, £205,379
- British Skin Foundation and British Society for Paediatric and Adolescent Dermatology Small Grant Award 2023, entitled: "A qualitative study to evaluate the content validity of the Psoriasis Area Severity Index (PASI), as a measure of disease severity in children and young people with psoriasis.", Co-investigator, £10,000
- British Skin Foundation PhD Studentship entitled: "Do cholesterol-lowering treatments bring on or make atopic eczema worse? Triangulating evidence from genes and the clinic.", Principal Investigator and Supervisor, £95,000

### **Publication metrics (updated December 2023)**

- PubMed/Medline listed publications 90; Citations 3106; h-index 26

### **Research committee / group positions**

- Co-Deputy Chair for the UK Dermatology Clinical Trials Network
- British Association of Dermatologists Research subcommittee member
- European Dermato-Epidemiology Network steering committee member
- UK Keratinocyte Cancer Collaborative (UKKCC) steering committee member, Epidemiology workstream
- UK-GRASS steering committee member
- British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) steering committee and study group member
- Global Guidelines in Dermatology Mapping Project, Principal Investigator
- Guideline development group member, British Association of Dermatologists Biologics therapy for psoriasis and (chair) methotrexate guidelines
- Member of the Greater Manchester Dermatology AI Delivery Group

### **University roles**

- Integrated Clinical Academic Training, University of Manchester, Clinical Pharmacology & Therapeutics theme co-lead
- Academic Advisor to the MBChB programme, Year 1 medical students

### **PhD students**

- Duc Binh Phan, funded by Psoriasis Association PhD Studentship from January 2022, Primary supervisor
- Heber Bright, funded by Psoriasis Association PhD Studentship from January 2023, Primary supervisor

### **PhD examiner**

- 1<sup>st</sup> year continuation report – Liezel Griffin
- Internal examiner – Ahmad Sherbini

## Peer-reviewed publications

### Original research articles

- Al-Janabi A, Alabas OA, **Yiu ZZN**, Foulkes AC, Eyre S, Khan AR, Reynolds NJ, Smith CH, Griffiths CEM, Warren RB; BADBIR Study Group. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis. *JAMA Dermatol*. 2023 Dec 6:e234846. doi: 10.1001/jamadermatol.2023.4846.
- Alabas OA, Mason KJ, **Yiu ZZN**, Warren RB, Dand N, Barker JN, Smith CH, Griffiths CEM; BADBIR study groups; BSTOP study groups. The association of age at psoriasis onset and HLA-C\*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). *Br J Dermatol*. 2023 Dec 5:ljad481. doi: 10.1093/bjd/ljad481.
- Hughes DM, Coronado JIC, Schofield P, **Yiu ZZN**, Zhao SS. The predictive accuracy of cardiovascular risk prediction tools in inflammatory arthritis and psoriasis: an observational validation study using the Clinical Practice Research Datalink. *Rheumatology (Oxford)*. 2023 Nov 15:kead610. doi: 10.1093/rheumatology/kead610.
- Mason KJ, Alabas OA, Dand N, Warren RB, Reynolds NJ, Barker JNWN, **Yiu ZZN**, Smith CH, Griffiths CEM; BADBIR Study Group. Characteristics of “Super-Responders” and “Super-Non-Responders” to First Biologic Monotherapy for Psoriasis: a Nested Case-control study. *Br J Dermatol*. 2023 November 9 doi: 10.1093/bjd/ljad446.
- Drucker AM, Lam M, Elsayi R, Prieto-Merino D, Malek R, Ellis AG, **Yiu ZZN**, Rochweg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Schmitt J, Flohr C. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. *Br J Dermatol*. 2023 Oct 13:ljad393. doi: 10.1093/bjd/ljad393.
- Chen TC, Wang TC, **Yiu ZZN**, Lee MS, Chen LC, Chan KA, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas (GPA). Risk of serious infection and infection mortality in patients with psoriasis: a nationwide cohort study using the Taiwan National Health Insurance claims database. *J Eur Acad Dermatol Venereol*. 2023 Aug 23. doi: 10.1111/jdv.19466.
- Yen H, Yen H, Huang CH, Huang IH, Hung WK, Su HJ, Tai CC, Haw WY, Flohr C, **Yiu ZZN**, Chi CC. Systematic review and critical appraisal of urticaria clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (GUIDEMAP). *J Allergy Clin Immunol Pract*. 2023 Jul 12:S2213-2198(23)00773-0.
- Phan DB, Elyoussfi S, Stevenson M, Lunt M, Warren RB, **Yiu ZZN**. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies. *JAMA Dermatol*. 2023 May 31. doi: 10.1001/jamadermatol.2023.1338.
- Alabas OA, Mason KJ, **Yiu ZZN**, Warren RB, Lunt M, Smith CH, Griffiths CEM; BADBIR Study Group. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). *Br J Dermatol*. 2023 May 25:ljad179. doi: 10.1093/bjd/ljad179.
- Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CEM, Lunt M, Warren RB, **Yiu ZZN**. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: A drug utilisation study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). *Br J Dermatol*. 2023 Apr 5:ljad107. doi: 10.1093/bjd/ljad107.
- **Yiu ZZN**, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM. Drug Survival for Effectiveness and Safety of Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis: Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). *JAMA Dermatol*. 2022 Oct 1;158(10):1131-1141.
- Alabas OA, Mason KJ, **Yiu ZZN**, Hampton PJ, Reynolds NJ, Owen CM, Bewley A, Laws PM, Warren RB, Lunt M, Smith CH, Griffiths CEM. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. *Br J Dermatol* 2023 (in press)
- Machado PM, Schäfer M, Mahil SK, Liew J, Gossec L, Dand N, Pfeil A, Strangfeld A, Regierer AC, Fautrel B, Alonso CG, Saad CGS, Griffiths CEM, Lomater C, Miceli-Richard C, Wendling D, Alpizar Rodriguez D, Wiek D, Mateus EF, Sirotych E, Soriano ER, Ribeiro FM, Omura F, Rajão Martins F, Santos H, Dau J, Barker JN, Hausmann J, Hyrich KL, Gensler L, Silva L, Jacobsohn L, Carmona L, Pinheiro MM, Zelaya MD, Severina MLÁ, Yates M, Dubreuil M, Gore-Massy M, Romeo N, Haroon N, Sufka P, Grainger R, Hasseli R, Lawson-Tovey S,

- Bhana S, Pham T, Olofsson T, Bautista-Molano W, Wallace ZS, **Yiu ZZN**, Yazdany J, Robinson PC, Smith CH. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. *Ann Rheum Dis*. 2023 Feb 14;ard-2022-223499. doi: 10.1136/ard-2022-223499. Epub ahead of print. PMID: 36787993.
- Zhao SS, **Yiu ZZN**, Barton A, Bowes J. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study. *JAMA Dermatol*. 2023 Jan 25:e226051. doi: 10.1001/jamadermatol.2022.6051.
  - Quirke-McFarlane S, Weinman J, Cook ES, **Yiu ZZN**, Dand N, Langan SM, Bechman K, Tsakok T, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Barbosa IA, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisoni P, Jullien D, Lambert J, Naldi L, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Galloway JB, Griffiths CEM, Barker JN, Norton S, Smith CH, Mahil SK; PsoProtect study group. Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. *Br J Dermatol*. 2022 Dec 23;ljac144. doi: 10.1093/bjd/ljac144. Epub ahead of print. PMID: 36763806.
  - Al-Janabi A, Ra A, Littlewood Z, Foulkes AC, Hunter HJA, Chinoy H, Moriarty CA, Hyrich KL, Limdi JK, **Yiu ZZN**, Griffiths CE, Warren RB. The effect of immunomodulators on seroconversion to BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. *Br J Dermatol*. 2022 (in press)
  - Asfour L, De Brito M, Al-Janabi A, Haw WY, Johnson A, Flohr C, **Yiu ZZN**. Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a systematic review of alopecia areata clinical practice guidelines. *Clin Exp Dermatol*. 2022 (in press)
  - Haw WY, Al-Janabi A, Arents BWM, Asfour L, Exton LS, Grindlay D, Khan SS, Manounah L, Yen H, Chi CC, van Zuuren EJ, Flohr C, **Yiu ZZN**. Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines. *Br J Dermatol*. 2021;185(4):736-744.
  - Yen H, Huang CH, Huang IH, Hung WK, Su HJ, Yen H, Tai CC, Haw WY, Flohr C, **Yiu ZZN**, Chi CC. Systematic review and critical appraisal of psoriasis clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (GUIDEMAP). *Br J Dermatol* 2022 Epub ahead of print;doi: 10.1111/bjd.21047
  - Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, **Yiu ZZN**, Rochweg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Schmitt J, Flohr C. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. *JAMA Dermatol*. 2022 May 1;158(5):523-532. doi: 10.1001/jamadermatol.2022.0455.
  - Rutkowski D, Littlewood Z, Touyz SJJ, Collier N, Madan V, Ghura H, **Yiu ZZN**, Telfer N. Prevalence of wound complications following Mohs micrographic surgery: a cross-sectional study of 1000 patients undergoing Mohs surgery and wound repair in a UK teaching hospital. *Clin Exp Dermatol*. 2022 Apr 30. doi: 10.1111/ced.15226.
  - Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, **Yiu ZZN**, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups. Differences in Clinical Features and Comorbid Burden between HLA-C\*06:02 Carrier Groups in >9,000 People with Psoriasis. *J Invest Dermatol*. 2022 Jun;142(6):1617-1628.e10.
  - Izadi Z, Brenner EJ, Mahil SK, Dand N, **Yiu ZZN**, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazedo Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D'Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirolich E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, Kappelman MD; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. *JAMA Netw Open*. 2021 Oct 1;4(10):e2129639.
  - **Yiu ZZN**, Mason K, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab

and Ustekinumab in Psoriasis: a study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) *JAMA Dermatol*. 2021 Jan 1;157(1):66-73.

- Mahil SK, Yates M, Langan SM, **Yiu ZZN**, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, De La Cruz C, Di Meglio P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo-Ortega H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Griffiths CM, Barker JN, Brown MA, Galloway JB, Smith CH. Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. *Br J Dermatol*. 2020 Dec 23. doi: 10.1111/bjd.19755.
- Mahil SK, Dand N, Mason KJ, **Yiu ZZN**, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Teresa Rossi M, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Eng CS, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman E, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CEM, Barker JN, Smith CH; PsoProtect study group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global cross-sectional study. *J Allergy Clin Immunol*. 2020;16:S0091-6749(20)31413-5
- **Yiu ZZN**, Parisi R, Lunt M, Warren RB, Griffiths CEM, Langan SM, Ashcroft DM. Risk of Hospitalisation and Death Due to Infection in People With Psoriasis: A Population-based Cohort Study Using the Clinical Practice Research Datalink. *Br J Dermatol*. 2020 Mar 28. doi: 10.1111/bjd.19052. (in press)
- Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, **Yiu ZZN**, Uthman OA, Mohd Mustapa MF, Smith CH. Comparing the Efficacy and Tolerability of Biologic Therapies in Psoriasis: An Updated Network Meta-Analysis. *Br J Dermatol*. 2020;183(2):404-406.
- **Yiu ZZN**, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: A Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). *Br J Dermatol* 2020;183(2):294-302.
- Drucker AM, Ellis AG, Mashayekhi S, **Yiu ZZN**, Rochweg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Küster D, Siegels D, Schmitt J, Flohr C. Systemic immunomodulatory treatments for atopic dermatitis: a systematic review and network meta-analysis. *JAMA Dermatol* 2020 Apr 22;156(6):1-10.
- **Yiu ZZN**, Mason KJ, Barker JNWN, Hampton PJ, McElhone K, Smith CH, Warren RB, Griffiths CEM, Lunt M, Burden AD; BADBIR Study Group. A Standardisation Approach to Compare Treatment Safety and Effectiveness Outcomes between Clinical Trials and Real World Populations in Psoriasis. *Br J Dermatol* 2019 Dec;181(6):1265-1271.
- Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, **Yiu ZZN**, Griffiths CEM, Burden AD; BADBIR Study Group. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. *JAMA Dermatol*. 2018 May 1;154(5):581-588.
- Mason KJ, Williams S, **Yiu ZZN**, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM. Persistence and Effectiveness of Non-Biologic Systemic Therapies for Moderate-Severe Psoriasis in Adults: a Systematic Review. *Br J Dermatol* 2019 Aug;181(2):256-264.
- **Yiu ZZN**, Sorbe C, Lunt M, Rustenbach SJ, Kuhl L, Augustin M, Mason KJ, Ashcroft DM, Griffiths CEM, Warren RB; BADBIR Study Group. Development and Validation of a Multivariable Risk Prediction Model for Serious Infection in Patients with Psoriasis Receiving Systemic Therapy. *Br J Dermatol* 2019 Apr;180(4):894-901.
- **Yiu ZZ**, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds N, Ormerod AD, Griffiths CE, Warren RB; BADBIR Study Group. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). *Br J Dermatol* 2019;180:329-337
- **Yiu ZZ**, Smith CH, Ormerod A, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds N, Griffiths CE, Warren RB. Risk of serious infection associated with biologic therapies in psoriasis: A prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). *J Invest Dermatol* 2018 Mar;138(3):534-541.
- **Yiu ZZ**, Exton LS, Jabbar-Lopez Z, Mustapa MFM, Samarasekera EJ, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Ashcroft DM, Griffiths CEM, Smith CH, Warren RB. Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. *J Invest Dermatol*. 2016 Aug;136(8):1584-91

- Jabbar-Lopez ZK, **Yiu ZZN**, Ward V, Exton LS, Mohd Mustapa MF, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH. Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. *J Invest Dermatol*. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27. Erratum in: *J Invest Dermatol*. 2021 Feb;141(2):463. PMID: 28457908; PMCID: PMC5519491.
- Rungapiromnan W, **Yiu ZZN**, Warren RB, Griffiths CE, Ashcroft DM. Impact of Biologic Therapies on Risk of Major Adverse Cardiac Events in Patients with Psoriasis: Systematic Review and Meta-analysis of Randomised Controlled Trials. *Br J Dermatol* 2017 Apr;176(4):890-901
- Warren RB\*, Smith CH\*, **Yiu ZZ\***, Ashcroft DM, Barker JN, Burden AD, Lunt M, McElhone K, Ormerod AD, Owen CM, Reynolds NJ, Griffiths CE. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). *J Invest Dermatol*. 2015;135(11):2632-40 (\*joint first authors)
- Iskandar IY, Ashcroft DM, Warren RB, **Yiu ZZ**, Mcelhone K, Lunt M, Barker JN, Burden AD, Ormerod AD, Reynolds NJ, Smith CH, Griffiths CE. Demographics and disease characteristics of psoriasis patients enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR). *Br J Dermatol*. 2015;173(2):510-8
- Theodorakopoulou E\*, **Yiu ZZ\***, Bundy C, Chularojanamontri L, Gittins M, Jamieson LA, Motta L, Warren RB, Griffiths CE. Early and late onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. *Br J Dermatol* 2016;175(5):1038-1044 (\*joint first authors)

#### Research Letters

- Venables ZC, Gran S, Levell NJ, **Yiu ZZN**, Proby CM. International melanoma and non-melanoma skin cancer mortality trends - is it time to re-focus our attention? *Clin Exp Dermatol*. 2023 Dec 7:llad438. doi: 10.1093/ced/llad438.
- Bechman K, Cook ES, Dand N, **Yiu ZZN**, Tsakok T, Meynell F, Coker B, Vincent A, Bachelez H, Barbosa I, Brown MA, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Kelly J, Lambert J, Lancelot C, Langan SM, Mason KJ, McAteer H, Moorhead L, Naldi L, Norton S, Puig L, Spuls PI, Torres T, Urmston D, Vesty A, Warren RB, Waweru H, Weinman J, Griffiths CM, Barker JN, Smith CH, Galloway JB, Mahil SK; PsoProtect study group. Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. *Br J Dermatol*. 2022 Aug;187(2):254-256.
- **Yiu ZZN**, Harding G, Griffiths CEM, Warren RB, McMullen E, Hunter HJA. Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study. *Br J Dermatol*. 2021 Mar 17. doi: 10.1111/bjd.20062.
- Mahil SK, Yates M, **Yiu Z**, Langan SM, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Lambert J, Naldi L, Norton S, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Brown MA, Galloway JB, Griffiths CM, Barker JN, Smith CH; PsoProtect study group. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. *J Eur Acad Dermatol Venereol*. 2021 Oct;35(10):e636-e640
- Al-Janabi A, Littlewood Z, Griffiths CEM, Hunter HJA, Chinoy H, Moriarty C, **Yiu ZZN**, Warren RB. Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. *Br J Dermatol* 2021 May 12. doi: 10.1111/bjd.20479.
- de Brito M, Stevens BR, **Yiu ZZN**. Can artificial intelligence be used for accurate remote scoring of the Psoriasis Area and Severity Index in adult patients with plaque psoriasis? *Br J Dermatol*. 2021 Dec;185(6):1262-1264. doi: 10.1111/bjd.20663.
- Mahil SK\*, **Yiu ZZN\***, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters A, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls P, Griffiths CEM, Barker J, Irvine AD, Smith CH; Secure-AD, PsoPROTECT study groups. Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. *Br J Dermatol*. 2020 Apr 29. doi: 10.1111/bjd.19161. (in press) (\*joint first authors)
- **Yiu ZZN**, Jabbar-Lopez ZK, Ahmed S, Mohd Mustapa MF, Chi CC, Flohr C. Results from the BJD survey on readership views towards clinical practice guidelines. *Br J Dermatol* 2020 Jul;183(1):188-189.

#### Guidelines

- Smith CH, **Yiu ZZN**, Bale T, Burden AD, Coates LC, Eckert E, Longley N, Mahil SK, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Woolf RT, Mansour Kiaee Z, Constantin AM, Ezejimofor MC, Exton LS, Mohd Mustapa MF; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023 - a pragmatic update. *Br J Dermatol*. 2023 Sep 22;ljad347. doi: 10.1093/bjd/ljad347.
- Smith CH, **Yiu ZZ**, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update. *Br J Dermatol*. 2020;183(4):628-637.
- Smith CH, Jabbar-Lopez ZK, **Yiu ZZ**, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Peleva E, Pottinger E, Samarasekera EJ, Stoddart J, Strudwicke C, Venning V, Warren RB, Exton LS, Mustapa MFM. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. *Br J Dermatol* 2017 Sep;177(3):628-636

#### Protocols

- Phan DB, Jourdain H, González-Quesada A, Zureik M, Rivera-Díaz R, Sahuquillo-Torralla A, Descalzo-Gallego MA, Lunt M, Garcia-Doval I, Sbidian E, Warren RB, **Yiu ZZN**. Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study. *BMJ Open*. 2023 Jul 14;13(7):e075197.
- Drucker AM, Ellis A, Jabbar-Lopez Z, **Yiu ZZN**, Arents BWM, Burton T, Spuls PI, Küster D, Schmitt J, Flohr C. Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. *BMJ Open*. 2018 Aug 29;8(8):e023061.

#### Meeting reports

- **Yiu ZZN**, Barker JNWN, Barnes MR, Di Meglio P, Emsley R, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; PSORT Consortium. Meeting Report: Psoriasis Stratification to Optimise Relevant Therapy Showcase. *J Invest Dermatol*. 2021 Mar 23;S0022-202X(21)01010-1.

#### Editorials and Review articles

- Al-Janabi A, **Yiu ZZN**. Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management. *Psoriasis (Auckl)*. 2022 Jan 6;12:1-14. doi: 10.2147/PTT.S328575.
- de Brito M, **Yiu ZZN**. Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say? *Am J Clin Dermatol*. 2021 Sep;22(5):587-601.
- **Yiu ZZN**, Mason KJ, Smith CH, Griffiths CEM; BADBIR Study Group. The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. *Br J Dermatol* 2020 Dec;183(6):981-983.
- Malhi IS, **Yiu ZZN**. Algorithm based smartphone apps to assess risk of skin cancer in adults: critical appraisal of a systematic review. *Br J Dermatol*. 2021 Apr;184(4):638-639
- Asfour L, **Yiu ZZN**, Warren RB. How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting. *Expert Opin Drug Saf*. 2020 Mar 21:1-9
- Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, **Yiu ZZN**. Risankizumab versus ustekinumab for plaque psoriasis: a critical appraisal. *Br J Dermatol* 2019 Jun;180(6):1348-13
- **Yiu ZZ**, Warren RB. Ustekinumab for the treatment of psoriasis: an evidence update. *Semin Cutan Med Surg* 2018;37(3):143-147
- **Yiu ZZN**, Warren RB. Guselkumab for Psoriasis: A Critical Appraisal of Phase III Studies. *Immunotherapy*. 2018 Jan;10(1):67-75.
- **Yiu ZZN**, Warren RB. Raising standards for the evaluation of future psoriasis therapeutics: A critical checklist. *Clin Pharmacol Ther*. 2017 Oct;102(4):642-648.
- Hanley TL, **Yiu ZZ**. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. *Ther Clin Risk Manag*. 2017;13:315-323



- **Yiu ZZ**, Warren RB. The Potential Utility of Tildrakizumab: an Interleukin-23 Inhibitor for the Treatment of Psoriasis. *Expert Opin Investig Drugs* 2017;26(2):243-249
- **Yiu ZZ**. Disease-Specific Treatment Registries for Research – Psoriasis as an Exemplar. *Br J Dermatol* 2017;176:794-796
- **Yiu ZZ**, Warren RB. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis. *Am J Clin Dermatol*. 2016;17(3):191-200
- **Yiu ZZ**, Griffiths CE. Interleukin 17-A inhibition in the treatment of psoriasis. *Expert Rev Clin Immunol*. 2015 Nov 11:1-4
- **Yiu ZZ**, Warren RB. Efficacy and safety of emerging immunotherapies in psoriasis. *Immunotherapy*. 2015 Feb;7(2):119-33.
- **Yiu ZZ**, Warren RB, Mrowietz U, Griffiths CE. Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. *J Dermatolog Treat*. 2014 Nov 26:1-24
- **Yiu ZZ**, Griffiths CE, Warren RB. Safety of biologic therapies for psoriasis on reproductive potential and outcomes in males and females. *Br J Dermatol* 2014 Sep;171(3):485-91
- Ali FR, **Yiu ZZ**, Yell J. Potassium iodide: a Dickensian drug for dermatological disease. *Dermatology in practice* 2015;21:7-8
- Hanley T, Handford M, Lavery D, **Yiu ZZ**. Assessment and monitoring of biologic drug adverse events in patients with psoriasis. *Psoriasis: Targets and Therapy* 2016 April;6:41-54

#### Case reports

- Khoo AB, Ali FR, **Yiu ZZ**, Ferguson J. Carbamazepine induced Stevens-Johnson Syndrome. *BMJ Case Rep* 2016 Mar 11;2016. pii: bcr2016214926. doi: 10.1136/bcr-2016-214926
- Ali FR, **Yiu ZZ**, Ogden S. Minocycline-induced pigmentation of the skin and nails. *Postgrad Med J* 2015 Nov;91(1081):662
- **Yiu ZZ**, Ali FR, Griffiths CE. Paradoxical exacerbation of chronic plaque psoriasis by sorafenib. *Clin Exp Dermatol* 2016;41(4):407-9
- Ali FR, **Yiu ZZ**, Fitzgerald D. Inflammation of actinic keratoses during paclitaxel chemotherapy. *BMJ Case Rep*. 2015 Jun 8; pii: bcr2015209925. doi: 10.1136/bcr-2015-209925.
- **Yiu ZZ**, Madan V, Griffiths CE. Acne conglobata and adalimumab: use of tumour necrosis factor-alpha antagonists in treatment-resistant acne conglobata and review of the literature. *Clin Exp Dermatol* 2015;40(4):383-6
- **Yiu ZZ**, Ali FR, Wilson MS, Mowatt D, Lyon CC. Giant Condylomata Acuminata of Buschke and Lowenstein: A peristomal variant. *Int J Surg Case Rep* 2014;5:1014-1017

## Non peer-reviewed publications

### *Health Technology Assessment*

- Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, **Yiu ZZN**, Wittmann M. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. *Health Technol Assess*. 2024 Jan;28(4):1-113

### *Editorials*

- **Yiu ZZN**, Chi CC, Ingram JR, Flohr C. Checking for update...living systematic reviews and clinical practice guidelines in the BJD. *Br J Dermatol*. 2022 May;186(5):761-762.
- **Yiu ZZN**, Chi CC, Flohr C. All aboard the BJD for global dissemination of high-quality dermatology clinical practice guidelines. *Br J Dermatol* 2020 Jul;183(1):3-4

### *Commentaries*

- Alabas OA, **Yiu ZZN**. A sprinkle of methotrexate to go with biologics: a safe recipe? *Br J Dermatol*. 2024 Jan 3;ljad505. doi: 10.1093/bjd/ljad505.
- **Yiu ZZN**. Repurposing existing trial data to infer relative efficacy of biologics: guselkumab vs. ustekinumab for psoriasis. *Br J Dermatol* 2020;183(2):202-203.
- Parisi R, **Yiu ZZN**. The worldwide epidemiology of rosacea. *Br J Dermatol* 2018;179(2):239-240
- **Yiu ZZ**. Psoriasis and increased drug utilisation: A true burden of psoriasis or potential surveillance bias of comorbidities? *Br J Dermatol* 2017;176:566-567

### *Correspondence*

- Smith CH, Mahil SK, **Yiu ZZN**, Bale T, Burden AD, Coates LC, McGuire A, Murphy R, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF. Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis-Correction. *J Invest Dermatol*. 2021 Jan;141(1):177-181.
- Rungapiromnan W, **Yiu ZZN**, Warren RB, Griffiths CEM, Ashcroft DM. Reply to 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials': reply from the authors. *Br J Dermatol* 2017 Dec;177(6):1766-1767.
- Jabbar-Lopez ZK, **Yiu ZZ**, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH. Author Reply to: Letter to the Editor in Response to recently published article, 'Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis' *J Invest Dermatol*. 2017 Dec;137(12):2644-2646.

### *Book chapters*

- **Yiu Z**, Warren R, Menter A. Introduction. In: Warren R, Menter A ed. *Handbook of Psoriasis and Psoriatic Arthritis*. Adis, pp.1-5

### Prizes

- BSMD Medical Dermatology Prize for Best Oral Presentation, BAD Annual Meeting 2023
- CIHR-IMHA Inclusive Research Excellence Prizes – Open Science competition and Team Science competition entitled, “Living systematic review and network meta-analysis of systemic immunomodulatory treatments for atopic dermatitis”
- British Association of Dermatologists, Clive Archer THESIS Fellowship 2019
- Royal College of Physicians, Turner-Warwick Lecturer 2019, North Western Region
- Winner of Poster Competition Group A, Clinical Academics in Training Annual Conference, The Academy of Medical Sciences, 2018
- 1<sup>st</sup> place Spotlight Poster session, Biologics and Biosimilars, 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2018
- Royal Society of Medicine Trainee Research Prize, Dermatology section, 2018
- 1<sup>st</sup> place Spotlight Poster session, Biologics and Biosimilars, 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2017
- Best overall team, Eighth NIHR Infrastructure Doctoral Research Training Camp: The Art of Communication, 2017
- Second place, Academic Foundation Showcase. Presented by Dr Jon Miles, Foundation Academic Lead and Associate Dean, North Western Deanery, and Prof David Thompson, Academic lead for North West Integrated Academic Training Programme, University of Manchester

### Registration grant awards

- EADV-AAD Annual Meeting Registration Scholarship, AAD Annual Meeting in San Diego 2024
- Education grant to attend Psoriasis From Gene to Clinic, 2021
- Eli Lilly Scholarship registration: 29<sup>th</sup> Virtual EADV Congress
- Eli Lilly Healthcare Provider Restrictive Grant : 27<sup>th</sup> EADV Congress , Paris , France
- Scholarship to attend 34<sup>th</sup> International Conference for Pharmacoepidemiology, 2018
- ESDR travel grant, IID meeting 2018
- BAD-AAD Annual Meeting Registration Scholarship, AAD Annual Meeting in San Diego 2018
- NIHR/BAD Travel Bursary to the European Society for Dermatology Research, 2017
- Scholarship to attend 33<sup>rd</sup> International Conference for Pharmacoepidemiology, 2017
- Michael Hornstein Memorial Scholarship to attend 26<sup>th</sup> EADV Congress in Geneva, Switzerland, 2017
- Education grant to attend Psoriasis From Gene to Clinic, 2017
- Travel grant to attend the ESDR, 2017

## Presentations

### *Oral presentations*

#### *International*

- Title: Drug survival of interleukin-23 p19 inhibitors compared to other biologics for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register  
Location: Berlin, Germany  
Organisation: European Academy for Dermatology and Venereology Congress 2023, Late-breaking oral plenary session  
Date: 11/10/2023
- Title: Global Guidelines in Dermatology Mapping Project (GUIDEMAP) – an accessible initiative to catalogue and appraise guidelines for the treatment of skin conditions worldwide  
Location: Toronto, Canada  
Organisation: Guidelines International Network 20<sup>th</sup> Annual Conference  
Date: 23/09/2022
- Title: Effect Modification of Biologic Survival by Patient Characteristics: A Step Towards Precision Medicine in the Treatment of Psoriasis  
Location: Copenhagen, Denmark  
Organisation: International Conference on Pharmacoepidemiology 2022  
Date: 27/08/2022
- Title: Drug survival of guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in psoriasis: a prospective observational study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)  
Location: London  
Organisation: Psoriasis From Gene to Clinic, 9<sup>th</sup> International Congress  
Date: 10/12/2021
- Title: Development and Internal Validation of a risk prediction model for serious infection in patients with psoriasis using the British Association of Dermatologists Biologic Interventions Register (BADBIR).  
Location: Orlando, Florida, US  
Organisation: International Investigative Dermatology meeting 2018  
Date: 19/05/2018
- Title: A Propensity Score Weighting Approach to Compare Registry and Trial Populations of Patients with Psoriasis  
Location: Berlin, Germany  
Organisation: 2<sup>nd</sup> European Dermato-Epidemiology Network Forum  
Date: 16/03/2018
- Title: Risk of Serious Infections Associated with Biologic Therapies in Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)  
Location: Salzburg, Austria  
Organisation: European Society for Dermatological Research, European Dermato-epidemiology Network symposium  
Date: 28/09/2017
- Title: Persistence with biologic therapies for the treatment of moderate-to-severe psoriasis: a prospective observational study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)  
Location: London  
Organisation: Psoriasis From Gene to Clinic, 7<sup>th</sup> International Congress  
Date: 13/12/2014
- Title: Cutaneous nodule in a patient receiving infliximab for psoriasis  
Location: Brussels, Belgium  
Organisation: International Masterclass in Psoriasis, LEO Pharma  
Date: 03/05/2014

#### *National*

- Title: Does methotrexate affect treatment persistence or effectiveness of adalimumab for psoriasis? A trial emulation cohort study  
Location: Liverpool  
Organisation: 103<sup>rd</sup> British Association of Dermatologists Annual Meeting 2023

- Title: Effect modification of biologic survival by patient characteristics: a prospective cohort study from the British Association of Dermatologists Biologic and Immunomodulators Register  
Location: Glasgow, Scotland  
Organisation: 102<sup>nd</sup> British Association of Dermatologists Annual Meeting 2022
- Title: Drug survival of adalimumab, secukinumab and ustekinumab in psoriasis: does biological treatment history matter?  
Location: Virtual  
Organisation: 100<sup>th</sup> Virtual British Association of Dermatologists Annual Meeting 2020
- Title: An Investigation into the Association and Prediction of Serious Infections in Patients on Biologic Therapies for Psoriasis  
Location: ACC Liverpool  
Organisation: 99<sup>th</sup> British Association of Dermatologists Annual Meeting – Clive Archer THESIS Fellowship 2019  
Date: 04/07/2019
- Title: An Investigation into the Association and Prediction of Serious Infections in Patients on Biologic Therapies for Psoriasis  
Location: Liverpool Medical Institute  
Organisation: Royal College of Physicians – Turner-Warwick Lecture  
Date: 14/03/2019
- Title: Timing of the last dose of biologic therapy and risk of postsurgical infections in patients with psoriasis.  
Location: Edinburgh  
Organisation: 98<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 04/07/2018
- Title: An Investigation into the Association and Prediction of Serious Infection in Patients with Psoriasis  
Location: London  
Organisation: Royal Society of Medicine, Dermatology Section, Trainee Research Prize  
Date: 19/04/2018
- Title: Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis  
Location: Birmingham  
Organisation: 96<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 06/07/2016
- Title: Differential persistence of four biologic therapies for the treatment of moderate-to-severe psoriasis: a prospective observational study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)  
Location: Manchester  
Organisation: 95<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 09/07/2015
- Title: Infliximab associated psoriasiform alopecia  
Location: Manchester  
Organisation: 95<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 07/07/2015
- Title: Recurrent infected eczema and leg ulceration (Prolidase deficiency)  
Location: Manchester, Salford Royal NHS Foundation Trust  
Organisation: British Society for Paediatric Dermatology  
Date: 08/11/2014
- Title: Photoprotective properties of endogenous urocanic acid in human skin  
Location: Manchester  
Organisation: British Society for Investigative Dermatology  
Date: 12/04/2011

*Local*

- Title: Do biologic therapies increase the risk of serious infection in patients with psoriasis?  
Location: Manchester  
Organisation: Mancunian Skin Club, The University of Manchester  
Date: 15/01/2018

- Title: Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register  
Location: Manchester  
Organisation: University of Manchester Doctoral Academy PhD Conference  
Date: 16/05/2017
- Title: Drug persistence of biologic therapies for the treatment of psoriasis  
Location: Manchester  
Organisation: University of Manchester and the North Western Deanery, 8<sup>th</sup> Integrated Clinical Academic Training Annual Meeting  
Date: 21/11/2014
- Title: Cutaneous nodule in a patient receiving infliximab for psoriasis  
Location: Manchester  
Organisation: Dermatology department, Centre of Excellence Event, Salford Royal NHS Foundation Trust  
Date: 19/09/2014
- Title: Photoprotective properties of endogenous urocanic acid in human skin  
Location: Manchester  
Organisation: Academic Foundation Showcase, Academic Foundation Committee, Northwestern Deanery  
Date: 01/07/2011

*Invited national and international oral presentations*

- Title: Use of Registries in Dermatology Research  
Location: Singapore  
Organisation: 25<sup>th</sup> World Congress of Dermatology, 2023  
Date: 07/07/2023
- Title: Update on new treatments and research findings  
Location: Birmingham  
Organisation: Psoriasis Association UK Annual Meeting  
Date: 17/06/2023
- Title: Dermatology, Epidemiology, Drugs, and Me  
Location: Willan House, BAD, London  
Organisation: British Association of Dermatologists / THESIS / BSID / UK DCTN Research Course  
Date: 09/06/2023
- Title: How to put Evidence Based Dermatology into practice  
Location: Milan, Italy  
Organisation: 31<sup>st</sup> EADV Congress  
Date: 09/09/2022
- Title: An overview of the state of clinical practice guidelines in Dermatology  
Location: Paris, France  
Organisation: 7<sup>th</sup> Congress of the Skin Inflammation and Psoriasis International Network  
Date: 07/07/2022
- Title: Effectiveness of Systemic Treatments for Psoriasis – Data from the British Association of Dermatologists Biologics and Immunomodulators Register  
Location: Virtual; Peru, Lima  
Organisation: Dermeeting CME Event, Janssen  
Date: 11/06/2022
- Title: Lessons learned from BADBIR  
Location: Spire, RCP, Liverpool  
Organisation: RCP-BAD – Celebrating the Skin we are in  
Date: 26/05/2022
- Title: Evaluation of Tumour Necrosis Factor Inhibitor Biosimilars in the UK: a planned study from BADBIR  
Location: Virtual  
Organisation: Psoriasis Association Annual Conference  
Date: 19/06/2021
- Title: Updates on PsoProtect and PsoProtectMe  
Location: Virtual

Organisation: 19th ESDaP Congress & 2nd Brain:Skin Colloquium  
Date: 12/06/2021

- Title: BADBIR highlights  
Location: Virtual  
Organisation: 100<sup>th</sup> Virtual British Association of Dermatologists Meeting 2020
- Title: Clinical Outcomes from BADBIR / PSORT – An Integrated UK and Ireland Collaborative Network  
Location: London  
Organisation: PSORT / British Association of Dermatologists  
Date: 18/11/2019
- Title: Updates in BADBIR – safety outcomes  
Location: Liverpool  
Organisation: 99<sup>th</sup> British Association of Dermatologists Annual Meeting, BADBIR session  
Date: 03/07/2019
- Title: Updates in BADBIR – safety outcomes  
Location: Harrogate  
Organisation: British Dermatological Nursing Group Annual Meeting, BADBIR session  
Date: 25/06/2019
- Title: Do biologic therapies increase the risk of serious infection in patients with psoriasis?  
Location: Fife, Scotland  
Organisation: Scottish Dermatological Society Meeting  
Date: 06/06/2019
- Title: Do biologic therapies increase the risk of serious infection in patients with psoriasis?  
Location: Manchester  
Organisation: School of Biological Sciences Annual Event, Plenary speaker, University of Manchester  
Date: 11/01/2019
- Hosted Journal club afternoon session at the 98<sup>th</sup> British Association of Dermatologists Annual Meeting, 05/07/2018
- Title: An Investigation into the Association and Prediction of Serious Infection in Patients with Psoriasis  
Location: Harrogate  
Organisation: British Dermatological Nursing Group Annual Meeting, BADBIR session  
Date: 26/06/2018
- Title: An Investigation into the Association and Prediction of Serious Infection in Patients with Psoriasis  
Location: Orlando, Florida, US  
Organisation: International Investigative Dermatology meeting 2018, Future Leaders Symposium  
Date: 16/05/2018
- Title: Updates to BAD biologics guideline 2017 / Updates on BADBIR  
Location: Manchester  
Organisation: British Dermatological Nursing Group Biologics Study Day  
Date: 13/03/2017
- Title: BADBIR: an unparalleled opportunity for research and training  
Location: Liverpool  
Organisation: 97<sup>th</sup> British Association of Dermatologists Annual Meeting, BADBIR session  
Date: 05/07/2017

*Accepted oral presentations – delivered by others*

- Title: The role of direct immunofluorescence in leucocytoclastic vasculitis  
Location: Orlando, Florida  
Organisation: American Academy of Dermatology  
Date: 04/03/2017  
Presenter: Dr Felicity Ferguson
- Title: Efficacy and Tolerability of Biologic Therapies for Psoriasis: Network Meta-Analysis  
Location: Munich  
Organisation: 46<sup>th</sup> Annual ESDR Meeting  
Date: 7-10/09/2016  
Presenter: Dr Zarif Jabbar-Lopez

### *Poster presentations*

- Title: Global Guidelines in Dermatology Mapping Project (GUIDEMAP) – an accessible initiative to catalogue and appraise guidelines for the treatment of skin conditions worldwide  
Location: Singapore  
Organisation: 25<sup>th</sup> World Congress of Dermatology  
Date: 3-8/07/2023
- Title: Association and Prediction of Serious Infection in Patients with Psoriasis on Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)  
Location: Milan  
Organisation: 24<sup>th</sup> World Congress of Dermatology  
Date: 10-15/06/2019
- Title: Examining the Risk of Serious Infection in Patient with Psoriasis on Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)  
Location: Edinburgh  
Organisation: Clinical Academics in Training Annual Conference, The Academy of Medical Sciences  
Date: 08/11/2018
- Title: Development and Internal Validation of a Multivariable Risk Prediction Model for Serious Infection in Patients With Psoriasis  
Location: Prague  
Organisation: 34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management  
Date: 22-26/08/2018
- Title: Timing of the Last Dose of Biologic Therapy and Risk of Post-Surgical Infections in Patients with Psoriasis  
Location: Prague  
Organisation: 34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management  
Date: 22-26/08/2018
- Title: A Propensity-Score Weighting Approach to Compare Registry and Trial Populations of Patients with Psoriasis on Biologic Therapies  
Location: Prague  
Organisation: 34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management  
Date: 22-26/08/2018
- Title: Risk of Serious Infections Associated with Biologic Therapies in Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)  
Location: Manchester  
Organisation: Association of Physicians Annual Meeting 2018  
Date: 12-13/04/2018
- Title: Infliximab is Associated with an Increased Risk of Serious Infection in Patients with Psoriasis  
Location: London  
Organisation: Psoriasis Gene to Clinic Congress 2017  
Date: 30/11 – 02/12/2017
- Title: Risk of Serious Infections Associated with Biologic Therapies in Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)  
Location: Salzburg, Austria  
Organisation: International Psoriasis Council Poster walk, 47<sup>th</sup> Annual ESDR Meeting  
Date: 29/09/2017
- Title: Examining the Risk of Serious Infection in Patients with Psoriasis on Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)  
Location: Montreal  
Organisation: 33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management  
Date: 26-30/08/2017
- Title: Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies  
Location: Dublin  
Organisation: 32<sup>nd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management  
Date: 25-28/08/2016



- Title: Impact of Biologic Therapies on Risk of Major Adverse Cardiac Events in Patients with Psoriasis: Meta-analysis of Randomised Controlled Trials  
Location: Birmingham  
Organisation: 96<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 07/2016
- Title: What comes through the Mohs clinic door?  
Location: Birmingham  
Organisation: 96<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 07/2016
- Title: How long do patients stay on biologic therapies for the treatment of psoriasis?  
Location: Manchester  
Organisation: Postgraduate Summer Research Showcase, The University of Manchester  
Date: 30/06/2016
- Title: How long do patients stay on biologic therapies for the treatment of psoriasis?  
Location: The Queens Hotel, Leeds  
Organisation: 9<sup>th</sup> Annual NIHR Trainee Meeting  
Date: 24-25/11/2015
- Title: A prospective audit of dermatology surgery complication rate  
Location: Copenhagen  
Organisation: 24<sup>th</sup> EADV Congress  
Date: 10/2015
- Title: Infliximab-Associated Psoriasiform Alopecia  
Location: Honolulu, Hawaii  
Organisation: American College of Gastroenterology Annual Scientific Meeting 2015  
Date: 18-21/10/2015
- Title: Paradoxical exacerbation of chronic plaque psoriasis by sorafenib  
Location: Manchester  
Organisation: 95<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 07/2015
- Title: Inflammation of actinic keratosis during paclitaxel chemotherapy  
Location: Manchester  
Organisation: 95<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 07/2014
- Title: Giant Condylomata Acuminata of Buschke and Lowenstein: A Peristomal Variant  
Location: Glasgow  
Organisation: 94<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 07/2014
- Title: Safety of systemic therapies for psoriasis on reproductive potential and outcomes  
Location: Glasgow  
Organisation: 94<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 07/2014
- Title: Young patients with complicated perianal and peristomal predicaments  
Location: Glasgow  
Organisation: 94<sup>th</sup> British Association of Dermatologists Annual Meeting  
Date: 07/2014
- Title: Larva currens in disseminated *Strongyloides Stercoralis* – a case report  
Location: London  
Organisation: British Association of Dermatologists, Dermdoc Meeting  
Date: 16/05/2011
- Title: Reduced time to image-guided placement of intra-abdominal drain is associated with better patient outcome  
Location: Oxford, John Radcliffe Hospital  
Organisation: Research in Clinical Practice, Oxford University Clinical Academic Graduate School  
Date: 10/11/2010

- Title: Reduced time to image-guided placement of intra-abdominal drain is associated with better patient outcome  
Location: London  
Organisation: British Institute of Radiology  
Date: 10/12/2010

### **Public and Patient Involvement**

- Psoriasis: Next Generation Healthcare and Psoriasis Shout Out Healthcare Trailer Roadshow – guest speaker  
Location: Citylabs, Manchester  
Date: 11/10/2018
- “Let’s Talk Psoriasis” presentation and Psoriasis Shout Out Healthcare Trailer Roadshow – guest speaker  
Location: Salford Royal NHS Foundation Trust  
Date: 22/06/2016

### **Clinical audit presentations**

- Title: Reaudit on referrals to the Mohs Assessment Clinic  
Location: Salford Royal NHS Foundation Trust  
Date of presentation: 12/03/2020  
Department of Dermatology, audit meeting
- Title: Direct Immunofluorescence in Leucocytoclastic Vasculitis  
Location: Salford Royal NHS Foundation Trust  
Date of presentation: 08/09/2016  
Department of Dermatology, audit meeting
- Title: What comes through the Mohs Clinic Door?  
Location: Salford Royal NHS Foundation Trust  
Date of presentation: 08/09/2016  
Department of Dermatology, audit meeting
- Title: A prospective audit of dermatology surgery complication rate  
Location: Salford Royal NHS Foundation Trust  
Date of presentation: September 2015  
Department of Dermatology, audit meeting
- Title: Re-audit of Dermatology Ward Referrals  
Location: Salford Royal NHS Foundation Trust  
Date of presentation: May 2014  
Department of Dermatology, audit meeting
- Title: Proton Pump Inhibitor audit  
Location: Sorrel Group Practice, Salford  
Date of presentation: July 2011
- Title: Audit on inpatient transfer for PCI  
Location: SRFT  
Date: April 2010, Department of Cardiology meeting

### **Management and leadership experience**

- Invited judge for the BMJ Awards 2019, Dermatology Team of the Year, 24/04/2019
- Invited judge for the BMJ Awards 2020, Dermatology Team of the Year, 07/10/2020
- Invited judge for the BMJ Awards 2021, Dermatology Team of the Year, 23/09/2021
- Member of the BAD Biologics Guideline Development Group 2017-2020
- Associate College Tutor, Royal College of Physicians, 2011-2012 – at Trafford General Hospital
- Panel member for Dermatology ST3 (Resident/Registrar) interviews, Manchester Conference Centre, 23/04/2015; 01/10/2015; 28/04/2016; 21/09/2016; 04/10/2017

### **Advisory roles**

- Clinical expert for BMJ Technology Assessment Group – Single Technology Appraisal of upadacitinib for atopic dermatitis
- Clinical expert for BMJ Technology Assessment Group – Single Technology Appraisal of tralokinumab for atopic dermatitis

### **Peer reviewer for journals as listed**

- Since 2014, I have reviewed for the following journals: Journal of Investigative Dermatology, British Journal of Dermatology, JAMA Dermatology, Journal of the European Academy of Dermatology and Venerology, Clinical Experimental Dermatology, BMJ case reports, Acta Dermato-Venereologica, BMJ Open
- Publons identifier: [publons.com/a/1204938/](https://publons.com/a/1204938/); 67 verified reviews listed in Publons

### **Memberships**

- Association of Physicians of Great Britain and Ireland
- Cochrane
- Royal College of Physicians, London (MRCP), no:157443
- British Association of Dermatologists, no:018115
- European Academy of Dermatology and Venereology, no:11745
- European Society for Dermatological Research, no: 3961
- International Society for Pharmacoepidemiology, member, 2016-2020

## Research training

### Courses

#### Leadership and management

- ESDR Academy for Future Leaders in Dermatology: Management and Leadership Development Programme, Manchester, 29-30/11/2019; second course day 12/04/2021 online

#### Research training

- Mendelian Randomization – An online short course, MRC Intergrative Epidemiology Unit, University of Bristol, 21-23/04/2021
- Swiss Winter Epidemiology School, Wengen, 21-26/01/2019
- Manchester Digital Epidemiology Summer School, Arthritis Research UK Centre for Epidemiology – 18-20/07/2018
- Statistical Methods for Risk Prediction and Prognostic Models, Keele University, 7-9/03/2018
- Analysing Patient-Level Data using Hospital Episode Statistics (HES), University of York, 4-6/12/2017
- Eighth NIHR Infrastructure Doctoral Research Training Camp: The Art of Communication, Leeds, 12-14/07/2017
- Getting to Grips with Evidence Based Dermatology, Nottingham, 25-27/01/2016
- Systematic Reviews and Meta-Analysis in Action, NCGC, London, 19/11/2015
- MRC fellowship scheme in Clinical Pharmacology and Therapeutics teaching module: Biologics Bench to Bedside, Manchester, 27/03/2015
- Clinical research and epidemiology, EADV fostering course, Rotterdam, 7-11/07/2014
- STATA course, University of Manchester, Arthritis Research UK Epidemiology Unit, 2014

#### Dermatology and Research related

- Euroderm Excellence 2021 course, Euroderm Excellence for Future Leaders, European Dermatology Forum, 29-30/04/2021
- Dermatopathology One Day Crash Course, Oxbridge Medica, London, 19/09/2015
- SCE Dermatology revision course, Galderma, Birmingham, 26-28/06/2015
- British Society for Dermatological Surgery, Annual Surgery Workshop, 12-14/05/2014
- International Psoriasis Master Class, LEO Pharma, Brussels, Belgium, 2-3/5/2014
- British Association of Dermatologists, British Society for Medical Dermatology, Essential Medical Dermatology Course, 5-7/03/2014

#### Others

- Advanced Life Support, SRFT, 29/04/2010
- IMPACT (Ill Medical Patients' Acute Care and Treatment) course, Royal Guildford Hospital, 29/06/2010
- OSCE examiner course, The University of Manchester Medical School, 03/03/2011
- Leadership, Managing People and Building Teams, Miad, SRFT, 07/03/2011

## Education

- Academic advisor to 12 Year 1 MBChB students, University of Manchester
- Primary PhD supervisor to Duc Binh Phan for Psoriasis Association PhD studentship
- Supervisor to Dr Fatimah Khoda on MSc Experimental Medicine dissertation
- Supervisor to Year 3 MBChB students on projects on the Applied Personal Excellence Pathway, dedicated time to research projects within the Medicine degree
- Supervision of dermatology Academic Clinical Fellow Dr Ahmed Hawwa
- Regular teaching of Evidence based Dermatology to dermatology registrars
- Regular clinical teaching to Year 4 MBChB on dermatology rotation
- North Western General Internal Medicine SpR teaching day, 21/11/2016, Lectured on Severe Cutaneous Adverse Reactions
- PGCert Workplace-based Postgraduate Medical Education, Module 1, Edge Hill University, passed with Merit, 2014-2015
- Regular teacher, Medicines safety tutorial, Dermatology, 2014-2015
- DERMSOC presenter (Year 3-5 medical students), 02/12/2013
- OSCE examiner, Undergraduate Medical Examination, Formative Year 3 OSCE Examinations, 21/02/2013
- OSCE examiner, Undergraduate Medical Examination, Year 3 OSCE Examinations, 7-9 June 2011
- Regular teacher of Final year medical students (2011-2014)
- Regular teacher of Third year medical students
- Member of student team for development of Cultural Awareness Communication Workshop, 2007
- Assisted Communication Skills tuition to medical students, September 2006